Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo
QR678 Neo®; Hair re-growth
androgenetic alopecia
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
17
09
2021
accepted:
13
12
2021
pubmed:
9
1
2022
medline:
5
2
2022
entrez:
8
1
2022
Statut:
ppublish
Résumé
Intradermal administration of QR678 Neo This study aims to evaluate effectiveness and safety of hair re-growth factor formulation at multiple centers for reduction of hair fall and regrowth of hair in androgenetic alopecia and female pattern hair loss. An open-label, prospective, and interventional study was carried out at multiple centers of different countries. A total of 2428 patients with androgenetic alopecia and female pattern hair loss within the age range of 18-65 years were included in the study. Hair pull test, global photographic assessment, videomicroscopic assessment tests were performed at the beginning, after fourth and eighth sessions, and self-assessment through questionnaire related to satisfaction and side effects was carried out at beginning and at after eight session. Hair pull test was positive in only 12% of the patients after eight sessions. Beneficial results were noted in the global assessment score (mean-6) after fourth session and eighth session (mean-8). Huge improvement was noted in terminal hair count, vellus hair count, and hair density after eighth sessions. Also, with self-assessment score, a higher satisfaction score was noted. On long-term follow-up as well, no side effects were noted. Intradermal administration of QR678 Neo
Sections du résumé
BACKGROUND
BACKGROUND
Intradermal administration of QR678 Neo
AIM
OBJECTIVE
This study aims to evaluate effectiveness and safety of hair re-growth factor formulation at multiple centers for reduction of hair fall and regrowth of hair in androgenetic alopecia and female pattern hair loss.
MATERIALS AND METHODS
METHODS
An open-label, prospective, and interventional study was carried out at multiple centers of different countries. A total of 2428 patients with androgenetic alopecia and female pattern hair loss within the age range of 18-65 years were included in the study. Hair pull test, global photographic assessment, videomicroscopic assessment tests were performed at the beginning, after fourth and eighth sessions, and self-assessment through questionnaire related to satisfaction and side effects was carried out at beginning and at after eight session.
RESULTS
RESULTS
Hair pull test was positive in only 12% of the patients after eight sessions. Beneficial results were noted in the global assessment score (mean-6) after fourth session and eighth session (mean-8). Huge improvement was noted in terminal hair count, vellus hair count, and hair density after eighth sessions. Also, with self-assessment score, a higher satisfaction score was noted. On long-term follow-up as well, no side effects were noted.
CONCLUSION
CONCLUSIONS
Intradermal administration of QR678 Neo
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
Types de publication
Clinical Trial, Phase IV
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
580-589Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Cruz C, Costa C, Gomes A, Matamá T, Cavaco-Paulo A. Human hair and the impact of cosmetic procedures: a review on cleansing and shape-modulating cosmetics. Cosmetics. 2016;3:26.
Rogers NE, Avram MR. Medical treatments for male & female pattern hair loss. J Am Acad Dermatol. 2008;59:547-566.
Orme S, Cullen DR, Messenger AG. Diffuse female hair loss: are androgens necessary? Br J Dermatol. 1999;141(3):521-523.
Yip L, Zaloumis S, Irwin D. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009;161:289-294.
Cartwright T, Endean N, Porter A. Illness perceptions, coping and quality of life in patients with alopecia. Br J Dermatol. 2009;160(5):1034-1039. doi:10.1111/j.1365-2133.2008.09014.x
Korabel H, Dudek D, Jaworek A, Wojas-Pelc A. Psychodermatology: psychological and psychiatrical aspects of aspects of dermatology. Przegl Lek. 2008;65(244):248.
Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001;27(1):53-54.
Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4:1-11.
Zimber MP, Ziering C, Zeigler F, et al. Hair regrowth following a Wnt- & follistatin containing treatment: safety & efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol. 2011;10:1308-1312.
Olsen EA, Weiner MS, Delong ER, Pinnell SR. Topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1985;13:185-192.
Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of androgenic alopecia. J Am Acad of Dermatol. 1998;39:578-589.
Price VH. Treatment of hair loss. N Engl J Med. 1999;341:964-973.
Ebling FG, Hale PA, Randall VA. Hormones & hair growth. In: Goldsmith LA, editor. Biochemistry & physiology of the skin, 2nd ed. Clarendon Press; 1991:660-690.
Parsley WM, Perez-Meza D. Review of factors affecting the growth & survival of follicular grafts. J Cutan Aesthet Surg. 2010;3:69-75.
Reese RJ. Autologous platelet rich plasma: what do we know? Important concepts relevant to hair restoration surgery. Hair Transplant Forum Intl. 2010;20(1):14-17.
Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20:369-379.
Kapoor R, Shome D, Vadera S. QR 678 hair growth factors formulation - In vivo cellular toxicity & in vivo animal efficacy study. Plast Reconstr Surg Open. 2020;8:e2843.
Kapoor R, Shome D, Doshi K, Vadera S, Patel G, Kumar V. Evaluation of efficacy of QR678® and QR678® Neo hair growth factor formulation in the treatment of persistent chemotherapy-induced alopecia caused due to cytotoxic chemotherapy-A prospective pilot study. J Cosmet Dermatol. 2020;19:1-10.
Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab. 2019;104(7):2875-2891.
Goldberg LJ, Lenzy Y. Nutrition and hair. Clin Dermatol. 2010;28:412-419.
Finner AM. Nutrition and hair: deficiencies and supplements. Dermatol Clin. 2013;31:167-172.
Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017;7:1-10.
Kapoor R, Shome D, Vadera S, Ram S. QR678 & QR678 Neo Vs PRP. A randomized, comparative, prospective study. J Cosmet Dermatol. 2020;19:1-9.
Kiichiro Y, Brown LF, Michael D. Control of hair growth & follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107:409-417.
Danilenko DM, Ring BD, Yanagihara D, et al. Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, & differentiation. Normalization of the nu/nu follicular differentiation defect & amelioration of chemotherapy-induced alopecia. Am J Pathol. 1995;147:145-154.
Jones JI, Clemmons DR. Insulin-like growth factors & their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
Lindner G, Botchkarev VA, Botchkareva NV, Ling G, Van der Veen C, Paus R. Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol. 1997;151:1601-1617.
Philp D, St-Surin S, Cha HJ, Moon HS, Kleinman HK, Elkin M. Thymosin beta 4 induces hair growth via stem cell migration & differentiation. Ann N Y Acad Sci. 2007;1112:95-103.
Lin WH, Xiang LJ, Shi HX, et al. Fibroblast growth factors stimulate hair growth through β-Catenin & Shh expression in C57BL/6 Mice. BioMed Res Int. 2015;2015:730139.
Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30:834-839.
Tawfik AA, Osman MAR. The effect of autologous activated platelet-rich plasma injection on female pattern hair loss: a randomized placebo-controlled study. J Cosmet Dermatol. 2017;17(1):47-53. 10.1111/jocd.12357
Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014;7:213-219.
Singhal P, Agarwal S, Dhot PS, Sayal SK. Efficacy of platelet-rich plasma in treatment of androgenic alopecia. Asian J Transfus Sci. 2015;9:159-162.
Kapoor R, Shome D, Doshi K, Patel G, Vadera S. Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS-A prospective study. J Cosmet Dermatol. 2020;19:1-10.
Shome D, Kapoor R, Doshi K, Patel G, Vadera S, Kumar V. Effectiveness of QR678 Neo® with intralesional corticosteroid Vs intralesional corticosteroid alone in the treatment of alopecia areata -A randomized, comparative, prospective study. J Cosmet Dermatol. 2022;21:358-367.
Evaluation of effectiveness of QR678® & QR678 Neo® hair growth factor formulation in post-hair transplant patients. Manuscript submitted to Journal of Cosmetic Dermatology.
Shome D, Kapoor R, Vadera S, Doshi K, Patel G, Khan M. Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 Neo® hair regrowth formulation in the treatment of androgenetic alopecia- A prospective study. J Cosmet Dermatol. 2021;20:1-9.
Shome D, Kapoor R, Doshi K, Patel G, Vadera S, Kumar V. QR 678® vs QR678® with 5% Minoxidil solution and oral Finasteride in the treatment of male androgenetic alopecia -A randomized, comparative, Prospective study. J Cosmet Dermatol. 2021;19:1-3.
Shome D, Kapoor R, Surana M, Vadera S, Shah R. Efficacy of QR678 Neo® hair growth factor formulation for the treatment of hair loss in Covid-19- induced persistent Telogen Effluvium-A prospective, clinical, single-blind study. J Cosmet Dermatol. 2021:1-8.